Inhibition of soluble epoxide hydrolases as a new treatment target for cardiac hypertrophy

This article has no abstract so we have provided the first paragraph of the full text.

Cardiac failure often results from sustained cardiac hypertrophy. The transcription factor nuclear factor kappa B (NFB) regulates the expression of genes involved in cellular response to stress and has previously been implicated in the development of cardiac hypertrophy. Soluble epoxide hydrolase (sEH) inhibitors increase levels of endogenous lipid epoxides such as epoxyeicosatrienoic acids, which can interfere with NFB-mediated gene transcription. Further investigations into this process in mice have lead Xu et al. to present sEH inhibitors as a possible novel treatment for cardiac hypertrophy.

ARTICLE NAVIGATION - ARTICLE TOOLS

• Full text
• Download PDF
• Send to a friend
• PDA services
• Permissions

ISSUE NAVIGATION - THIS ISSUE

• Table of Contents
• Previous article
• Next article